Lung Cancer Journal Articles

• Acute Respiratory Failure in Interstitial Lung Diseases What are the best strategies for managing acute respiratory failure in patients with interstitial lung diseases?
  BMC Pulmonary Medicine, July 2018
• Antibiotics Affect Activity of Immune Checkpoint Inhibitors Does the altering of gut microbiota by antibiotics reduce the efficacy of immune checkpoint inhibitors?
  Annals of Oncology, July 2018
• Sleep-Disordered Breathing in Newly Diagnosed Lung Cancer This study provides insight into the prevalence of sleep-disordered breathing among patients with newly-diagnosed lung cancer. What are the implications?
  BMC Pulmonary Medicine, July 2018
• Complex Glandular Patterns in Lung Adenocarcinoma This study provides new insight into the potential role of complex glandular patterns in clinical management of lung adenocarcinoma.
  American Journal of Clinical Pathology, July 2018
• 92-Gene Assay for Metastatic Cancer of Unknown Primary Does this 92-gene assay help clinicians manage patients with metastatic cancer of unknown primary?
  JCO Precision Oncology, July 2018
• Telerehabilitation for Chronic Respiratory Disease Is a home-based telerehabilitation program as effective as traditional pulmonary rehabilitation for patients with chronic respiratory disease?
  BMC Pulmonary Medicine, July 2018
• Eliminating the Age Cutoff in Staging of Thyroid Cancer In this article, the authors explore whether the recent change in the age cutoff point for thyroid cancer staging is appropriate.
  Journal of Clinical Endocrinology & Metabolism, July 2018
• Latest Evidence for Particle Therapy in NSCLC What is the latest evidence on proton therapy for locally advanced lung cancer?
  Translational Lung Cancer Research, June 2018
• New Horizons in Systemic Anti-cancer Therapy in Older People What are the specific challenges faced by older persons with regards to systemic anti-cancer therapy, and how can we improve cancer therapeutics for this population?
  Age and Ageing, June 2018
• Hepatotoxicity of Immune Checkpoint Inhibitors Immune checkpoint inhibitors have proven utility as a new class of anticancer drugs, but carry with them the risk of hepatotoxic and other immune-related adverse events.
  Liver International, June 2018
• Time Is Up for PD-L1 Testing Standardization in Lung Cancer Rapid efforts are needed to determine analytical concordance between PD-L1 assays.
  Annals of Oncology, June 2018
• Aspergillus fumigatus During COPD Exacerbation A new study examines the clinical features and treatment outcomes of COPD patients with Aspergillus colonization.
  BMC Pulmonary Medicine, June 2018
• Medical Marijuana Use in Older Adults When is medical marijuana appropriate for use in older adults? This article reviews the evidence regarding indications for and risks of medical marijuana in this population.
  Journal of the American Geriatrics Society, June 2018
• Immune-Modifed Response Evaluation Criteria In Solid Tumors Does this modified RECIST criteria better reflect efficacy of cancer immunotherapy for solid tumors?
  Journal of Clinical Oncology, May 2018
• Combining Proton Beam Therapy and Immunotherapy Are outcomes improved in patients with NSCLC receiving both proton beam therapy and immunotherapy?
  Translational Lung Cancer Research, May 2018
• Sex Differences in Risk of Smoking-Associated Lung Cancer Does the association of smoking with lung cancer differ by gender?
  American Journal of Epidemiology, May 2018
• Spontaneous Regression of a Squamous Cell Lung Cancer What might be the mechanism behind the spontaneous regression of this patient's stage I squamous cell lung carcinoma?
  Journal of Medical Case Reports, May 2018
• Decreasing Incidence of Cancer After Liver Transplantation A decades-long study found a decrease in cancer risk after liver transplantation. What factors may have contributed to the decline?
  American Journal of Transplantation, May 2018
• Trends in Female Mortality in the United States, 1900-2010 This study analyzed historical trends in mortality rates among females from 1900 through 2010. How and why have causes of death changed over the decades, and what are the implications?
  Preventing Chronic Disease, May 2018
• CMS Should Have Required a Randomized Trial of F1CDx Authors give five reasons why CMS should have refrained from coverage of a 324-gene panel offered by Foundation Medicine in the absence of a randomized trial.
  Annals of Oncology, April 2018